Abstract Background The Khorana Score is a validated risk score for predicting 6‐month
incidence of cancer‐associated venous thromboembolism (CAT) among patients starting …

BACKGROUND: Recent studies suggest that thromboprophylaxis is beneficial in preventing
venous thromboembolism (VTE) in cancer outpatients, but this is not widely adopted …

Background. Retrospective studies have suggested an association between cancer-
associated venous thromboembolism (VTE) and patient survival. We evaluated a previously …

Introduction: The risk of venous thromboembolism (VTE) is increased in patients with cancer
and contributes to significant morbidity, treatment delays and mortality. The Khorana score is …

Background Current risk assessment models (RAMs) for prediction of venous
thromboembolism (VTE) risk in the outpatient cancer population have shown poor predictive …

The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

Background The Khorana score was developed to predict the risk of venous
thromboembolism (VTE) in cancer patients receiving chemotherapy. However, the utility of …

Venous thromboembolism (VTE) is a commonly encountered problem in patients with
cancer. In recent years, cancer treatment paradigm has shifted with most therapy offered in …

Current guidelines recommend that patients with cancer be assessed for venous
thromboembolism (VTE) risk at the time of chemotherapy initiation and periodically …

Importance The assessment of the risk of venous thromboembolism (VTE) among
outpatients with cancer represents an unsolved topic. Current international guidelines …